Reuters logo
BRIEF-Celyad reports promising early results at 1st dose level of solid arm of THINK trial
June 19, 2017 / 5:10 AM / 5 months ago

BRIEF-Celyad reports promising early results at 1st dose level of solid arm of THINK trial

June 19 (Reuters) - CELYAD SA:

* CELYAD REPORTS PROMISING EARLY RESULTS AT FIRST DOSE LEVEL OF THE SOLID ARM OF THE THINK TRIAL

* TWO METASTATIC COLORECTAL CANCER PATIENTS REPORTED AS STABLE DISEASE AT 3-MONTH FOLLOW-UP(REMOVES EXTRANEOUS WORDS)

* NO TOXICITY SIGNALS REPORTED UP TO NOW Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below